NCT01357668进行中（未招募）不适用
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
Bristol-Myers Squibb59 个研究点 分布在 22 个国家目标入组 800 人开始时间: 2013年1月30日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 800
- 试验地点
- 59
- 主要终点
- Incidence rate of autoimmune disorders
研究概览
简要总结
The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- — 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Incidence rate of autoimmune disorders
时间窗: 10 years
Incidence rate of serious infections
时间窗: 10 years
Incidence rate of malignancies
时间窗: 10 years
次要结局
- Number of serious adverse events(10 years)
- Number of targeted infections (Epstein-Barr virus, cytomegalovirus, papilloma virus, herpes zoster, tuberculosis and opportunistic infections)(10 years)
研究者
研究点 (59)
Loading locations...
相似试验
已完成
不适用
Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsRheumatoid ArthritisNCT02758769Bristol-Myers Squibb303
已完成
4 期
Abatacept in Juvenile DermatomyositisDermatomyositisNCT02594735George Washington University10
Unknown
不适用
Rituximab and Abatacept Effectiveness in Differential Treatment of Interstitial Lymphocytic Lung Disease in Children With Primary Immunodeficiencies.Interstitial Lymphocytic Lung DiseaseNCT04572620Federal Research Institute of Pediatric Hematology, Oncology and Immunology30
已完成
3 期
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT00484289Bristol-Myers Squibb217
终止
2 期
Abatacept in ANCA Associated VasculitisANCA-associated VasculitisNCT00482066Imperial College London7